

Since 1909, Grifols has worked to improve the health and well-being of people around the world through our plasma-derived medicines, diagnostic and screening technologies, and hospital products.

Headquartered in Barcelona, Spain, we are proud to employ over 24,000 people globally, including more than 2,800 people in North Carolina.

As an industry leader in producing plasma-derived medicines and transfusion medicine solutions, our four specialized business divisions develop, produce and market innovative solutions and services that are sold in more than 100 countries and regions.



#### BIOSCIENCE

Leading producer of plasma-derived medicines for the treatment of chronic, rare and, at times, life-threatening conditions.



#### DIAGNOSTIC

Advancing patient care with diagnostic solutions that improve disease detection and management and simplify laboratory operations.



#### HOSPITAL

Serving the needs of hospital pharmacies to contribute to safe, high-quality healthcare for patients worldwide.



#### BIO SUPPLIES

Supplying high-quality biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products.

## GRIFOLS ACROSS THE WORLD A GLOBAL COMPANY



Grifols subsidiaries

Manufacturing facilities:

- Bioscience
- Diagnostic
- Hospital
- Bio Supplies

VISIT [GRIFOLS.COM](http://GRIFOLS.COM) TO LEARN MORE

# GRIFOLS

# COMMITTED TO NORTH CAROLINA

# GRIFOLS

# PRODUCING PLASMA MEDICINES

What makes Grifols unique is that people, from donors to patients, are at the heart of everything we do. To fulfill our mission, we depend on the generosity of dedicated and committed plasma donors.

Plasma contains hundreds of essential proteins and antibodies vital to the body's ability to maintain critical functions. We are the largest collector of human plasma with nearly 300 plasma donation centers in the U.S. and Europe that provide Grifols with a dependable supply of the plasma needed to produce our medicines. The production of plasma-derived medicines is a multi-step process that can take up to 12 months to complete.



MUCH OF THIS ESSENTIAL WORK HAPPENS RIGHT HERE IN NORTH CAROLINA.



## PLASMA COLLECTION

Thanks to our donors' generosity, we are able to produce plasma-derived medicines that treat rare, chronic and, at times, life-threatening conditions. Grifols has 13 plasma donation centers that span eight counties in North Carolina. Each donation center is estimated to add \$5 million to the local economy.



## MANUFACTURING

Patients from around the world rely on Grifols plasma medicines produced in the Clayton community, which is home to our largest manufacturing facility. Here, plasma collected from donors is converted into medicines that treat chronic and rare diseases.



## CORPORATE SUPPORT

Our corporate employees in North Carolina are an essential part of making our company operate effectively around the world.



## EXPANSION

Grifols is committed to North Carolina. The company's extensive expansion efforts have stimulated the local economy and made Grifols the largest private employer in Johnston County.

- In North Carolina, Grifols employs over 2,800 employees between our Clayton, Research Triangle Park and Donor Center locations.
- Since 2011, Grifols has invested more than \$675 million in the Clayton site.
- With new facilities under construction, Grifols is expecting to create over 500 new jobs.



- ★ Clayton & RTP locations
- Donation Centers



At Grifols, innovation is our relentless search for new healthcare solutions for patients. It also means our continuous commitment to improving industrial processes aimed at achieving the highest quality and safety of our products and services.

Grifols' R&D+i projects focus on broadening the therapeutic potential of plasma proteins, enhancing the safety of blood transfusions, creating new solutions for hospitals and laboratories, and advancing intravenous therapies. Visit [grifols.com/innovation](http://grifols.com/innovation) to learn more about our latest projects.

€329M

Euro R&D+i Investment  
as of 2019

9

R&D+i Centers

1,100+

Employees work in R&D+i